Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01456052 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate Safety and Efficacy of Telotristat Etiprate (LX1606) in Participants With Acute, Mild to Moderate Ulcerative Colitis
A Phase 2 study of Ulcerative Colitis, sponsored by Lexicon Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 59
- Enrollment target
- 20
- Study locations
NCT01456052: Completed Phase 2 study of Ulcerative Colitis, sponsored by Lexicon Pharmaceuticals.
NCT01456052 is a Phase 2 study of Ulcerative Colitis that has completed, run by Lexicon Pharmaceuticals. The registered enrollment target is 59 participants, below the 2,057-participant average among 122 other Ulcerative Colitis trials with a reported enrollment target (97% lower). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01456052, a Phase 2 study of Ulcerative Colitis, has completed, sponsored by Lexicon Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 59 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a multicenter, placebo-controlled, parallel-group, pilot study to evaluate safety and preliminary effectiveness of two blinded dose levels of telotristat etiprate (LX1606) in participants with acute, mild to moderate ulcerative colitis on 5-aminosalicylic acid/mesalamine therapy.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Telotristat Etiprate
Study Locations (20)
Other
- Lexicon Investigational Site - Kaunas
- Lexicon Investigational Site - Klaipėda
- Lexicon Investigational Site - Šiauliai
- Lexicon Investigational Site - Vilnius
- Lexicon Investigational Site - Vilnius
- Lexicon Investigational Site - Krakow
- Lexicon Investigational Site - Lodz
- Lexicon Investigational Site - Sopot
- Lexicon Investigational Site - Warsaw
California
- Lexicon Investigational Site - Anaheim
- Lexicon Investigational Site - Santa Monica
New York
- Lexicon Investigational Site - Great Neck
- Lexicon Investigational Site - New York
Texas
- Lexicon Investigational Site - Houston
- Lexicon Investigational Site - San Antonio
Utah
- Lexicon Investigational Site - Ogden
- Lexicon Investigational Site - Sandy City
Arkansas
- Lexicon Investigational Site - Little Rock
Oklahoma
- Lexicon Investigational Site - Tulsa
Washington
- Lexicon Investigational Site - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2012-01-30 |
| Est. Completion | 2013-09-03 |
| Phase | Phase 2 |
What the finished NCT01456052 record still lists
NCT01456052 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 59 participants, a relatively small participant target, below the 2,057-participant average among 122 other Ulcerative Colitis trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Ulcerative Colitis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01456052 names 20 study sites across 8 states, led by Other, California, New York.
Frequently Asked Questions
What is clinical trial NCT01456052 about?
NCT01456052 is a clinical study titled "A Study to Evaluate Safety and Efficacy of Telotristat Etiprate (LX1606) in Participants With Acute, Mild to Moderate Ulcerative Colitis". This is a multicenter, placebo-controlled, parallel-group, pilot study to evaluate safety and preliminary effectiveness of two blinded dose levels of telotristat etiprate (LX1606) in participants with acute, mild to moderate ulcerative colitis on 5-aminosalicylic acid/mesalamine therapy.
What is the current status of trial NCT01456052?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 59 participants. The study started on 2012-01-30. Estimated completion is 2013-09-03.
What conditions does trial NCT01456052 study?
This clinical trial studies the following conditions: Ulcerative Colitis.
What interventions are being tested in trial NCT01456052?
The interventions under investigation include: Placebo (DRUG), Telotristat Etiprate (DRUG).
Who is sponsoring clinical trial NCT01456052?
This trial is sponsored by Lexicon Pharmaceuticals, which has 56 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01456052 being conducted?
This trial has 20 study locations across Arkansas, California, New York, Oklahoma, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ulcerative Colitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01456052's enrollment target sits among peer trials
59 81st of 122 higher than 41 of 122 other Ulcerative Colitis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ulcerative Colitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC)
RECRUITING · Phase 2
-
Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative Colitis
RECRUITING · Phase 2
-
A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis
RECRUITING · Phase 2
-
Treatment of UC With Novel Therapeutics
RECRUITING · Phase 2
-
A Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative Colitis
RECRUITING · Phase 2
-
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03801083 · 59 participants · Phase 2
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers
- NCT04332367 · 59 participants · Phase 2
Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance
- NCT05489575 · 59 participants · NA
CPAP for the Treatment of Supine Hypertension
- NCT06721689 · 59 participants · Phase 1
PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI